

28AB-ISMS15 **Discovery of Novel 2',4'-dimethyl-[4,5'-bithiazol]-2-yl Amino Derivatives as Orally-Bioavailable TRPV4 Antagonist for the Treatment of Pain**

○Naoki TSUNO¹, Akira YUKIMASA¹, Osamu YOSHIDA¹, Shinji SUZUKI¹, Hiromi NAKAI¹, Tomoyuki OGAWA¹, Motohiro FUJIU¹, Kenji TAKAYA¹, Azusa NOZU², Yusuke ICHIHASHI¹, Takatsugu INOUE¹, Tatsuhiko UENO¹, Hiroki YAMAGUCHI¹, Naotake KOBAYASHI¹, Hidetoshi MATSUDA³, Satoko FUNAKI⁴, Natsue YAMANADA¹, Miki TANIMURA¹, Yoko NISHIMURA⁴, Tetsuji ITO⁴, Daiki NAGAMATSU⁴, Shinya HISAKAWA⁴, Toshiyuki ASAKI¹, Narumi HORITA³, Miyuki YAMAMOTO¹, Mikie HINATA¹, Masahiko SOGA¹, Masayuki IMAI⁵, Yasuhide MORIOKA¹, Toshiyuki KANEMASA¹, Gaku SAKAGUCHI⁵, Yasuyoshi ISO¹

¹Discovery Research Laboratory for Core Therapeutic Areas, Shionogi & Co., Ltd., ²Discovery Research Laboratory for Innovative Frontier Medicines, Shionogi & Co., Ltd., ³Shionogi Techno Advance Research Co., Ltd.,

⁴Research Laboratory for Development, Shionogi & Co., Ltd., ⁵Pharmaceutical Research Division, Shionogi & Co., Ltd.

TRPV4 is one of a cation channel of the Transient Receptor Potential Vanilloid superfamily, which is activated by several stimuli such as hypo-osmotic, heat and chemical agonist 4-phorbol 12,13-didecanoate (4 α PDD). TRPV4 is widely expressed in various tissues, and the activation of TRPV4 can induce many physiological responses, and involve the development of various diseases. Recently, it was revealed that selective and competitive TRPV4 antagonist for 4 α PDD or osmotic stress showed an important role in pain. In our compound library, we identified 2',4'-dimethyl-[4,5'-bithiazol]-2-yl amino derivative as a novel TRPV4 antagonist by high-throughput screening against hypo-osmotic and 4 α PDD stimuli. Some orally-bioavailable compounds possess analgesic activity in pain model was identified by hit to lead optimization study.